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In colorectal cancer, tumor budding is associated with tumor progression and represents
an additional prognostic factor in the TNM classification. Tumor buds can be found
at the invasive front (peritumoral budding; PTB) and in the tumor center (intratumoral
budding; ITB) of primary tumors. Previous studies have shown that tumor buds are also
present in colorectal liver metastases (CRLM). Data on the prognostic and predictive
role in this clinical context are still sparse and no standardized approach to evaluate
budding in CRLM has been published so far. This study aimed to analyze and correlate
perimetastatic (PMB) and intrametastatic budding (IMB) on H&E and pancytokeratin
staining, compare it to budding results in corresponding primary tumors and to propose
a standardized scoring system in CRLM as the basis for future studies. Tumor tissue of
81 primary tumors and 139 corresponding CRLM was used for ngTMA construction.
For each primary tumor and metastasis, two punches from the center and two punches
from the periphery from areas with highest tumor budding density were included. TMA
slides were stained for H&E and pancytokeratin (Pan-CK). PTB, ITB, PMB, and IMB
were analyzed and classified as bd1, bd2, and bd3 according to ITBCC guidelines.
ITB and PTB as well as IMB and PMB showed significant correlation on H&E and
Pan-CK staining. No correlation was found for tumor bud counts in primary tumors and
corresponding metastases. The agreement for categorized tumor bud counts showed
fair to good agreement for metastases and poor agreement for primary tumors between
different classes on H&E and Pan-CK staining. Based on our results, tumor budding in
primary tumors and CRLM seems to be different processes which might be the results
of differing surrounding microenvironments. The evaluation of tumor budding in CRLM
is challenging in cases without desmoplastic stroma reaction or intense perimetastatic
ductular reaction. We therefore propose to evaluate tumor budding only in metastases
with desmoplastic stroma reaction based on H&E staining since important morphological
features are obscured on Pan-CK staining.
Keywords: tumor budding, metastasis, intratumoral budding, intrametastatic budding, peritumoral budding,
perimetastatic budding
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INTRODUCTION
In colorectal cancer, tumor budding is associated with tumor
progression, local and distant metastases (1) and is an additional
prognostic factor in the TNM classification published by the
UICC (2). In 2016, the international tumor budding consensus
conference (ITBCC) proposed a standardized scoring system,
validated by several studies over the last few years (3–12).
Additionally, the ITBCC highlighted the importance of tumor
budding especially in two clinical scenarios: in pT1 CRC, tumor
budding may be an indicator of an oncologic resection and in
stage II CRC of adjuvant therapy, respectively (13).
A geographic histological analysis of CRC revealed the
presence of tumor buds not only at the invasive tumor front
(peritumoral budding, PTB), but also within the main tumor
body (intratumoral budding, ITB) (14). The clinical value of ITB
is its potential assessment in preoperative rectal cancer biopsies
(15) and the prognostic significance shown now by several studies
(16, 17).
An additional clinical scenario for tumor budding may be
the management of stage IV CRC. The treatment of colorectal
cancer liver metastases (CRLM) includes surgery alone and/or
a combination with systemic chemotherapy. In a recent study,
tumor budding was analyzed on a monocentric patient cohort
(n = 229) which underwent a first surgical resection of CRLM
(18). Tumor budding was counted on H&E slides using a
quantitative method selecting the area with highest density
and counting sequential HPFs and shown to be a prognostic
factor in univariate, but not in multivariate analysis (18).
Nevertheless, there is not enough data in the literature to make
final conclusions on the prognostic or predictive value of tumor
budding in CRLM.
One of the main lessons learnt from the ITBCC is
the stepwise validation of promising histological biomarkers
and their potential value in daily practice. Therefore, we
embarked in this preliminary study with three well-defined
aims: first, to systematically analyze the geographic map of
tumor budding in CRLM by introducing two terms, namely
intrametastatic budding (IMB) and perimetastatic budding
(PMB) and difficulties associated with the assessment of budding
in hepatic resections; second, to score IMB and PMB on pan-
cytokeratin (Pan-CK) and H&E stained slides based on the
ITBCC method; third, to propose a scoring system for tumor
budding in CRLM as a basis for future large multi-centric
retrospective and prospective studies.
MATERIALS AND METHODS
Patient Cohort
Histological slides from a retrospective cohort of initially
110 patients surgically treated between 2000 and 2016 at
the Inselspital Bern for their primary CRC and synchronous
or metachronous CRLM were screened for tumor budding.
Tumors without tumor budding in either the primary CRC
or corresponding CRLM were excluded from the cohort. The
final cohort included 81 patients of which one patient had two
metachronous primary CRC. Formalin-fixed paraffin-embedded
tissues from 82 primary CRC and 139 corresponding CRLMwere
used for this study and their corresponding clinicopathological
data are summarized in Table 1.
Slide Scanning and Annotations
H&E slides of all cases were reviewed to identify tumor blocks
from primary tumors and liver metastases with highest density of
tumor buds at the tumor front and within the tumor. The tumor
front was defined as the desmoplastic stroma surrounding the
TABLE 1 | Clinicopathological features.
Clinicopathological features (N = 81)
Gender
Male 55
Female 26
Histological subtype (primary)
Adeno 80
Mucinous 1
Tumor location (primary)
Left 44
Right 34
Rectum 1
Rectosigmoid 3
pT
pT1 0
pT2 6
pT3 52
pT4 23
pN
pN0 19
pN1-2 62
Tumor grade (primary)
G1-2 59
G3 18
Neoadjuvant therapy 4
Lymphatic invasion (primary)
L0 13
L1 39
Venous invasion (primary)
V0 19
V1 41
Perineural invasion (primary)
Pn0 24
Pn1 21
MMR status
Deficient 4
Proficient 77
Time to metastasis
Synchronous 56
Metachronous 25
Number of metastases
Median 2
Range 1–9
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most advancing parts of the main tumor body. Only resection
specimens were considered for the study.
Selected tumor blocks were re-cut and slides were stained
for H&E. All H&E stained slides were scanned (Pannoramic
P250, 3D Histech, Hungary, 20× objective lens) and uploaded
onto a digital platform (http://ngtma.path.unibe.ch/casecenter).
Digital slides were reviewed and areas with highest density of
tumor budding were annotated using a TMA annotation tool
(Panoramic viewer v15.1 and TMA annotation tool, 3D Histech,
Hungary). Different colors for tumor front (blue color) and
center (red color) were used. Two annotations from the tumor
center and two annotations from the tumor front were placed
onto the digital slides whenever possible.
Next-Generation Tissue Microarray
(ngTMA®) Construction
Eighty-two blocks from primary tumors and 144 blocks from
liver metastases served as donor blocks for ngTMA construction.
In CRLM with only few vital tumor cells it was necessary to
include more than one tumor block. Donor blocks and annotated
digital slides were loaded into an automated tissue microarrayer
(Grandmaster, 3D Histech). An image of each donor block
was taken and superimposed onto the digital slide for exact
correspondence. After confirming each annotation, punches
with a diameter of 1mm from donor blocks were taken and
transferred into a recipient block. A total of 328 punches from
primary tumors (tumor front: 164; tumor center: 162) and a total
number of 560 punches from liver metastases (tumor front: 284;
tumor center: 276) were included in the ngTMA.
Immunohistochemistry
TMA blocks were sectioned at 2.5µm. Sections were mounted
on glass slides, dried and baked at 60◦C for 30min. H&E staining
and double immunohistochemistry for Pan-CK and CD8 were
performed. Double immunohistochemistry was performed using
Bond RX (Leica Biosystems). Slides were dewaxed using Bond
dewax solution (product code AR9222, Leica Biosystems). Heat-
induced epitope retrieval in citrate buffer based (code AR9640,
Leica Biosystems) at pH6 for 20min at 100◦C was followed by
incubation with primary mouse pancytokeratin antibody (Dako,
clone AE1/AE3, Ref M351501-2); dilution 1:400; for 30min.
Slides were incubated with HRP (horseradish peroxidase)-
polymer for 15min. Visualization was accomplished using 3,3-
Diaminobenzidine (DAB) for 10min, leading to a brown staining
signal (Bond polymer refine detection, Leica Biosystems, Ref
DS9800). As a second step, mouse CD8 antibody was used (Dako-
Agilent, clone C8/144B, Ref M7103); dilution 1:100; incubation
time 30min. Alkaline Phosphatase (AP)-polymer was used as
secondary antibody; incubation time 15min. Visualization was
accomplished using fast red resulting in a red chromogen
(Red polymer refine Detection, Leica Biosystems, Ref DS9390).
Samples were counterstained with hematoxylin and mounted
with Aquatex (Merck).
Evaluation of H&E and
Immunohistochemistry
All ngTMA slides were scanned (Pannoramic P250, 3DHistech,
Hungary, 20× objective lens) and evaluated using Scorenado, a
TMA analysis tool for digital TMA slides, as described previously
(19). Each tumor punch contained an area of 0.785 mm2. Only
Pan-CK staining was used to evaluated tumor budding in the
present study. Tumor buds were defined as single cells or cell
cluster of up to 4 tumor cells according to the ITBCC guidelines
(13). One experienced pathologist (A.L.) evaluated the number
of tumor buds on H&E and Pan-CK staining at the tumor
front (PTB and PMB) as well as intratumoral (ITB and IMB).
Representative examples for PMB and IMB are given in Figure 1.
Statistical Analysis
Descriptive statistics were performed to determine the number
of tumor buds in both H&E and CK, including mean,
minimum and maximum values across the center and tumor
front in both primary tumor and metastatic lesions. Pearson’s
correlation coefficient was used to determine the strength of
linear association between budding counts. P-values< 0.05 (two-
sided) were considered statistically significant. Kappa statistics
and 95%CI were used to investigate agreement in BD categories
between primary and metastatic tumors. The agreement was
again determined using intraclass correlation coefficients (ICC
values) for raw budding counts. All analyses were performed
using SAS v9.4, the SAS Institute (Cary, NC).
RESULTS
Tumor budding was assessed by counting all tumor buds per
punch on H&E and Pan-CK staining. For each patient the mean,
minimum and maximum number of ITB, PTB, IMB, and PMB
was recorded. Results are summarized in Table 2. A significant
difference was found between the mean number of tumor buds
in primary tumors and metastases on Pan-CK staining but not
on H&E (Table 3).
The correlation coefficients for ITB, PTB, IMB, and PMB on
H&E and Pan-CK staining are included in Table 4. ITB and
PTB showed significant correlation on H&E. IMB and PMB
showed significant correlation on H&E and Pan-CK staining. No
correlation was detected for tumor bud counts in primary tumors
and correspondingmetastases except for IMB onH&E staining in
comparison to ITB on Pan-CK staining.
Tumor bud counts from primaries and metastases were
categorized as bd1, bd2, and bd3 according to the ITBCC
guidelines (13) on H&E as well as on Pan-CK. The agreement for
categorized tumor bud counts were estimated using kappa values.
For metastases there was fair to good agreement. For primary
tumors, agreement was poor, between different classes on H&E
and Pan-CK staining. Results are given in Table 5.
DISCUSSION
The process of tumor budding in primary tumors and liver
metastases seems to be different. Although there was an
association between PTB and ITB as well as PMB and IMB,
respectively, a correlation between tumor budding in the primary
tumor and the corresponding metastases was not observed.
From a biological point of view, the present results could
make sense based on the following hypothesis. The formation
of tumor budding has been shown to be an important step in
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FIGURE 1 | Representative images of perimetastatic and intrametastatic budding on H&E and Pan-CK staining. Examples of tumor buds are indicated with an
asterisk.
TABLE 2 | Differences in the average number of ITB/IMB and PTB/PMB.
Stain Tissue Center/Front No. Mean Min Max
H&E Primaries Front 81 8.0 0 46
H&E Primaries Center 81 6.4 0 21
Pan-CK Primaries Front 81 12.3 0 53
Pan-CK Primaries Center 81 10.2 0 98
H&E Metastases Front 74 7.4 0 33
H&E Metastases Center 74 8.9 0 36
Pan-CK Metastases Front 74 9.0 0 59
Pan-CK Metastases Center 74 11.9 0 71
TABLE 3 | Number of buds in total metastasis and primary with means and test of
differences between matched samples.
Mean no. of buds P-value
Primaries H&E 7.2 0.6229
Metastases H&E 8.3
Primaries Pan-CK 11.3 0.0038
Metastases Pan-CK 7.3
the process of epithelial mesenchymal transition (EMT) (20–22).
As EMT is highly dependent on the tumor microenvironment,
one could expect different pathogenetic mechanisms of budding
in the liver parenchyma compared to the colorectal wall. The
formation of buds might be advantageous in one organ, but
obstructive or even destructive at the same time under different
circumstances. Consequently, tumor budding in CRLM may
differ from its role in primary CRC including the definition
of cut offs for therapeutic decision making as well as a
prognostic and predictive factor. The significant difference in
the mean number of tumor buds between primary tumors and
metastases on Pan-CK staining could provide further evidence
for this hypothesis.
These assumptions are corroborated by differences in
prognosis depending on the observed growth patterns in
CRLM. Desmoplastic CRLM are associated with a better
prognosis compared with the replacement or pushing type. The
replacement type of CRLM demonstrates a close proximity to
hepatic sinusoids and has been shown to be non-angiogenic.
The desmoplastic and pushing type on the other hand
reveal an angiogenic phenotype that might be disadvantageous
in a highly vascularized organ like the liver (23–28). A
broad rim of collagen could be even more hindering for
tumor progression and thus represents an explanation for the
observed differences in our study. Tumor cell migration and
angiogenesis is an important factor for tumor progression
in primary CRC but might be of no or lesser importance
in CRLM.
Up to now there are two publications which demonstrate
that tumor budding is a prognostic factor in CRLM based
on univariate, but not in multi-variate analysis (18, 29). This
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TABLE 4 | Correlation of intratumoral and intrametastatic budding (ITB/IMB) with peritumoral and perimetastatic budding (PTB/PMB).
H&E PTB H&E ITB Pan-CK PTB Pan-CK ITB H&E PMB H&E IMB Pan-CK PMB Pan-CK IMB
H&E PTB 1.0
H&E ITB 0.36* 1.0
Pan-CK PTB 0.27* 0.11 1.0
Pan-CK ITB −0.12 0.04 0.36 1.0
H&E PMB 0.03 0.11 −0.14 0.05 1.0
H&E IMB 0.08 0.09 −0.06 0.25* 0.6* 1.0
Pan-CK PMB 0.07 −0.08 −0.01 −0.01 0.44* 0.4* 1.0
Pan-CK IMB 0.01 −0.03 0.01 0.07 0.3* 0.3* 0.44* 1.0
Correlation coefficient indicated (r). Asterisk indicates p < 0.05.
TABLE 5 | Kappa values showing the concordance and percent agreement of bd scores for H&E and Pan-CK.
Pan-CK primaries front Kappa (95% CI) % Concordance
BD1 BD2 BD3
H&E primaries front BD1 12 3 14
BD2 4 4 13 0.14 (0–32) 42%
BD3 4 9 18
Pan-CK primaries center Kappa (95% CI) % Concordance
BD1 BD2 BD3
H&E primaries center BD1 13 8 13
BD2 8 2 13 0.03 (−0.2–0.14) 30%
BD3 10 4 9
Pan-CK metastases front Kappa (95% CI) % Concordance
BD1 BD2 BD3
H&E metastases front BD1 8 6 4 0.4 (0.2–0.6) 54%
BD2 4 4 6
BD3 1 2 15
Pan-CK metastases center Kappa (95% CI) % Concordance
BD1 BD2 BD3
H&E metastases center BD1 11 5 1 0.62 (0.4–0.8) 68.8%
BD2 2 6 3
BD3 1 3 16
result suggests that other factors such as differing components
of the microenvironment, including inflammatory and stromal
cells in the colon wall and in the liver may influence tumor
budding and therefore have a more important prognostic and/or
predictive role.
In primary CRC, pathologists using tumor budding in daily
practice know potential pitfalls such as intense peritumoral
inflammation, prominent stromal reaction with high numbers
of activated macrophages and glandular fragmentation (30).
Tumor buds are usually surrounded by desmoplastic stroma.
If this is not the case, retraction artifacts or vascular invasion
have to be ruled out. Pitfalls associated with the evaluation of
tumor budding in CRLM have not been described, yet. Before
using tumor budding in CRLM, its methodological challenges
needs to be elucidated and discussed. The hepatic microscopic
architecture differs significantly from the colon wall. The liver is a
highly vascularized organ, consisting of numerous arteries, veins
and sinusoids. These architectural differences permits growth
patterns other than the ones known from primary tumors
(25, 31, 32). Only the desmoplastic type of CRLM is likely
to demonstrate tumor buds. The pushing type, by definition,
should not manifest with single tumor cells or clusters at the
invasive front. The replacement type can exhibit single cells or
tumor cell clusters at the invasive front, but these are more
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FIGURE 2 | Methodical challenges for tumor budding evaluation in colorectal
liver metastases. (A) Single cells or tumor cells clusters in between
hepatocellular trabecula without obvious desmoplastic stroma reaction.
Examples of hepatocellular trabecula between infiltrating tumor cells are
indicated with arrows (B) Tumor buds and ductular reaction with reactive
changes in close proximity. Examples of ductular reaction are indicated with an
asterisk.
likely to represent vascular invasion due to their non-angiogenic
phenotype than actual tumor budding (Figure 2A). Second,
CRLM are often surrounded by a prominent ductular reaction
(Figure 2B) which can mimic tumor budding. Unfortunately,
there is no reliable immunohistochemical marker to differentiate
tumor buds from ductular reaction. Hence, the pathologist has
to rely on morphological features like nuclear-cytoplasmic-ratio,
anisokaryosis and hyperchromasia alone to distinguish bile ducts
from tumor buds.
In summary, our main goal was to systematically analyze
the tumor budding scoring systems in CRLM and therefore
focus only on the methodological aspects and not on its
predictive and prognostic role. Therefore, we suggest to
evaluate tumor budding only in CRLM with desmoplastic
stroma reaction on H&E stained slides using the ITBCC
method because of two reasons: First, infiltrating tumor
cells without surrounding stroma reaction cannot be reliably
differentiated from vascular invasion. Second, morphological
features to differentiate tumor buds from bile ducts are
more easily detected by H&E than by immunohistochemistry.
These aspects should be definitely considered in future large
retrospective/prospective trials including tumor budding in stage
IV CRC with liver metastases.
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